InsiderTrades.com logo
Jarrad Mattieu Aguirre net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jarrad Aguirre Biography and Net Worth

Chief Medical Officer of Lyell Immunopharma

Jarrad Aguirre, M.D., M.B.A., has served as our Chief Medical Officer since August 2026 and had joined as our Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio in 2025. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an M.D. and a M.B.A. from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a B.S. in Biology from Yale University.

What is Jarrad Mattieu Aguirre's net worth?

The estimated net worth of Jarrad Mattieu Aguirre is at least $149.13 thousand as of October 12th, 2026. Dr. Aguirre owns 19,857 shares of Lyell Immunopharma stock worth more than $149,126 as of October 14th. This net worth approximation does not reflect any other investments that Dr. Aguirre may own. Learn More about Jarrad Mattieu Aguirre's net worth.

How do I contact Jarrad Mattieu Aguirre?

The corporate mailing address for Dr. Aguirre and other Lyell Immunopharma executives is 201 Haskins Way, South San Francisco, CA, 94080. Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on Jarrad Mattieu Aguirre's contact information.

Has Jarrad Mattieu Aguirre been buying or selling shares of Lyell Immunopharma?

During the last ninety days, Jarrad Mattieu Aguirre has sold $3,641.86 in shares of Lyell Immunopharma stock. Most recently, Jarrad Mattieu Aguirre sold 422 shares of the business's stock in a transaction on Monday, October 12th. The shares were sold at an average price of $8.63, for a transaction totalling $3,641.86. Following the completion of the sale, the insider now directly owns 19,857 shares of the company's stock, valued at $171,365.91. Learn More on Jarrad Mattieu Aguirre's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Jarrad Aguirre (Chief Medical Officer), Otis Brawley (Director), Otis Brawley (Director), Stephen Hill (COO), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Gary Lee (Insider), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), Lynn Seely (CEO), and David Shook (Insider). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, insiders at the sold shares 21 times. They sold a total of 16,758 shares worth more than $341,156.75. The most recent insider tranaction occured on October, 12th when insider Jarrad Mattieu Aguirre sold 422 shares worth more than $3,641.86. Insiders at Lyell Immunopharma own 6.2% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 10/12/2026.

Jarrad Mattieu Aguirre Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/12/2026Sell422$8.63$3,641.8619,857View SEC Filing Icon  
See Full Table

Jarrad Mattieu Aguirre Buying and Selling Activity at Lyell Immunopharma

This chart shows Jarrad Mattieu Aguirre's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $7.51
Low: $7.39
High: $8.27

50 Day Range

MA: $12.32
Low: $7.51
High: $15.79

2 Week Range

Now: $7.51
Low: $7.39
High: $45.00

Volume

187,175 shs

Average Volume

157,676 shs

Market Capitalization

$184.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A